EPA:AMPLI - Euronext Paris - Matif - FR0012789667 - Common Stock - Currency: EUR
EPA:AMPLI (3/7/2025, 7:00:00 PM)
3.4
+0.04 (+1.19%)
The current stock price of AMPLI.PA is 3.4 EUR. In the past month the price decreased by -1.16%. In the past year, price increased by 2.41%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABL.DE | ABBOTT LABORATORIES | 29.15 | 217.38B | ||
IUI1.DE | INTUITIVE SURGICAL INC | 69.31 | 166.86B | ||
BSX.DE | BOSTON SCIENTIFIC CORP | 39.18 | 133.56B | ||
1BSX.MI | BOSTON SCIENTIFIC CORP | 39.52 | 133.38B | ||
1MDT.MI | MEDTRONIC PLC | 17.48 | 113.17B | ||
2M6.DE | MEDTRONIC PLC | 17.56 | 110.81B | ||
1SHL.MI | SIEMENS HEALTHINEERS AG | 25.27 | 60.49B | ||
BOX.DE | BECTON DICKINSON AND CO | 16.4 | 60.33B | ||
SHL.DE | SIEMENS HEALTHINEERS AG | 23.49 | 59.08B | ||
1EW.MI | EDWARDS LIFESCIENCES CORP | 26.07 | 39.21B | ||
EWL.DE | EDWARDS LIFESCIENCES CORP | 26.65 | 37.76B | ||
DC4.DE | DEXCOM INC | 48.5 | 28.81B |
Amplitude Surgical SAS engages in the manufacturing, marketing and design of orthopedic products. The company is headquartered in Valence, Auvergne-Rhone-Alpes and currently employs 428 full-time employees. The company went IPO on 2015-06-26. The firm offers the AMPLIVISION system, a computer navigation workstation and its related software, which is fully developed by the Company in collaboration with surgeons. Each implant is validated mechanically by creating models and running tests on simulators. Amplitude Surgical SAS relies on the expertise of its design offices and on scientific partnerships to internally design and develop its implants and automatic or computer-navigated instruments. The company operates through ofab Orthopedie, a strategic industrial subcontractor
AMPLITUDE SURGICAL SAS
11 Cours Jacques Offenbach
VALENCE AUVERGNE-RHONE-ALPES FR
Employees: 416
Company Website: https://www.amplitude-surgical.com/
Investor Relations: https://www.amplitude-surgical.com/en/documentation/reference-documents-financial-reports
Phone: 33475418741
The current stock price of AMPLI.PA is 3.4 EUR. The price increased by 1.19% in the last trading session.
The exchange symbol of AMPLITUDE SURGICAL SAS is AMPLI and it is listed on the Euronext Paris - Matif exchange.
AMPLI.PA stock is listed on the Euronext Paris - Matif exchange.
AMPLITUDE SURGICAL SAS (AMPLI.PA) has a market capitalization of 163.27M EUR. This makes AMPLI.PA a Micro Cap stock.
AMPLITUDE SURGICAL SAS (AMPLI.PA) currently has 416 employees.
AMPLITUDE SURGICAL SAS (AMPLI.PA) has a support level at 3.24 and a resistance level at 3.61. Check the full technical report for a detailed analysis of AMPLI.PA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AMPLI.PA does not pay a dividend.
AMPLITUDE SURGICAL SAS (AMPLI.PA) will report earnings on 2025-04-17.
The PE ratio for AMPLITUDE SURGICAL SAS (AMPLI.PA) is 113.33. This is based on the reported non-GAAP earnings per share of 0.03 and the current share price of 3.4 EUR. Check the full fundamental report for a full analysis of the valuation metrics for AMPLI.PA.
ChartMill assigns a technical rating of 4 / 10 to AMPLI.PA. When comparing the yearly performance of all stocks, AMPLI.PA turns out to be only a medium performer in the overall market: it outperformed 55.84% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to AMPLI.PA. AMPLI.PA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months AMPLI.PA reported a non-GAAP Earnings per Share(EPS) of 0.03. The EPS decreased by -96.07% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 1.44% | ||
ROA | 0.55% | ||
ROE | 1.59% | ||
Debt/Equity | 1.08 |
ChartMill assigns a Buy % Consensus number of 40% to AMPLI.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.